An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
G. Scagliotti
Honoraria - AstraZeneca; Lilly; Roche
I. Vynnychenko
No relevant relationships to disclose
Y. Ichinose
No relevant relationships to disclose
K. Park
Consultant or Advisory Role - Amgen
K. Kubota
No relevant relationships to disclose
F. H. Blackhall
Consultant or Advisory Role - Amgen (U)
Research Funding - Amgen
R. Pirker
No relevant relationships to disclose
R. Galiulin
No relevant relationships to disclose
T. Ciuleanu
Honoraria - Amgen
O. Sydorenko
No relevant relationships to disclose
M. Dediu
No relevant relationships to disclose
Z. Papai-Szekely
No relevant relationships to disclose
N. Martinez Banaclocha
No relevant relationships to disclose
S. McCoy
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
B. Yao
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. J. Hei
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
D. R. Spigel
Consultant or Advisory Role - Amgen (U)